Tesamorelin Acetate and Trametinib Dimethyl Sulfoxide

• Generic Name: tesamorelin
• Dosage Forms: n.a.
• Other Brand Names: Egrifta

Reduction of excess abdominal fat in patients with HIV-associated lipodystrophy. Selectively reduces visceral adipose tissue, preserves subcutaneous fat, and improves body image.

Long-term cardiovascular benefits and safety not known; carefully consider whether to continue the drug in patients who fail to achieve a substantial clinical response (based on degree of visceral adipose tissue reduction as measured by waist circumference or computed tomography [CT] scan).

Not indicated for weight loss management.

Insufficient evidence to support improved compliance with antiretroviral therapies in HIV-infected patients.

• Generic Name: trametinib
• Dosage Forms: n.a.
• Other Brand Names: Mekinist

In combination with dabrafenib as adjuvant therapy following complete resection of melanoma with BRAF V600E or V600K mutation and nodal involvement.

Alone or in combination with dabrafenib for treatment of unresectable or metastatic melanoma in selected patients with BRAF V600E or V600K mutation (designated an orphan drug by FDA as monotherapy or when used in combination for this use).

FDA-approved in vitro diagnostic test (e.g., THxID BRAF kit) required to confirm presence of BRAF V600E or V600K mutation prior to initiation of monotherapy or combination therapy.

Not recommended for use in patients with melanoma who have experienced disease progression following treatment with a BRAF inhibitor.

Used in combination with dabrafenib for treatment of metastatic non-small cell lung cancer (NSCLC) in patients with BRAF V600E mutation (designated an orphan drug by FDA when used in combination for this use).

FDA-approved diagnostic test (e.g., THxID BRAF kit) required to confirm presence of BRAF V600E mutation prior to initiation of therapy.

Used in combination with dabrafenib for treatment of locally advanced or metastatic anaplastic thyroid cancer in patients with BRAF V600E mutation when no satisfactory locoregional treatment options are available (designated an orphan drug by FDA when used in combination for this use).

FDA-approved diagnostic test (e.g., THxID BRAF kit) required to confirm presence of BRAF V600E mutation prior to initiation of therapy.